Completed PHASE2 INTERVENTIONAL 2-arm NCT01675570

A Study of RX-10045 in the Treatment of Dry Eye Disease

A Phase II, Multi-Center, Randomized, Placebo-Controlled, Double-Masked Study of RX-10045 (0.09%) in the Treatment of Dry Eye Disease

Sponsor: C.T. Development America, Inc.

Conditions Dry Eye Syndrome

Interventions RX-10045 Vehicle for RX-10045

Updated 6 times since 2017 Last updated: Feb 7, 2013 Started: Aug 31, 2012 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Dry Eye Syndrome, this trial is completed. The trial is conducted by C.T. Development America, Inc. and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Aug 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

C.T. Development America, Inc.

Data source: C.T. Development America, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Andover, United States